MedTrace Logo

A Study of GC012F in Patients With Relapsed/Refractory Multiple Myeloma

NCT06235229 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 110

Last updated 2026-02-25

No results posted yet for this study

Summary

This study is a single-arm, open-lable, phase I/II study to evaluate the efficacy and safety of GC012F in subjects with relapsed/refractory multiple myeloma.

Conditions

Interventions

BIOLOGICAL

GC012F

GC012F is a BCMA/CD19 dual CAR product

Sponsors & Collaborators

  • Gracell Biotechnologies (Shanghai) Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-12-26
Primary Completion
2026-03-02
Completion
2026-03-02

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06235229 on ClinicalTrials.gov